• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • Teses e Dissertações
  • PPG - Medicina (Endocrinologia e Metabologia)
  • View Item
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • Teses e Dissertações
  • PPG - Medicina (Endocrinologia e Metabologia)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Inércia clínica na intensificação da terapia com insulina em pacientes com Diabetes mellitus tipo 2 de um centro de diabetes público, terciário e com limitações no arsenal terapêutico farmacológico

Thumbnail
Date
2019-02-28
Author
Alvarenga, Marcelo Alves [UNIFESP]
Advisor
Chacra, Antonio Roberto [UNIFESP]
Type
Dissertação de mestrado
Metadata
Show full item record
Abstract
Background: Clinical inertia is related to the difficulty of achieving and maintaining optimal glycemic control. It has been extensively studied the delay of the period to insulin introduction in type 2 diabetes mellitus (T2DM) patients. This study aims to evaluate clinical inertia of insulin treatment intensification in a group of T2DM patients followed at a tertiary public Diabetes Center with limited pharmacologic armamentarium (Metformin, Sulphonylurea and Human Insulin). Methods: This is a real life retrospective record based study with T2DM patients. Demographic, clinical and laboratory characteristics were reviewed. Clinical inertia was considered when the patients did not achieve the individualized glycemic goals and there were no changes on insulin daily dose in the period. Results: We studied 323 T2DM patients on insulin therapy (plus Metformin and or Sulphonylurea) for a period of 2 years. The insulin daily dose did not change in the period and the glycated hemoglobin (A1c) ranged from 8.8 + 1.8% to 8.7 + 1.7% (basal vs 1st year; ns) and to 8.5 + 1.8% (basal vs 2nd year; p = 0.035). The clinical inertia prevalence was 65.8% (basal), 61.9% (after 1 year) and 58.2% (after 2 years; basal vs 1st year vs 2nd year; ns). In a subgroup of 100 patients, we also studied the first 2 years after insulin introduction. The insulin daily dose ranged from 0.22 + 0.12 to 0.32 + 0.24 IU/kg of body weight/day (basal vs 1st year; p < 0.001) and to 0.39 + 0.26 IU/kg of body weight/day (basal vs 2nd year; p < 0.05). The A1c ranged from 9.6 + 2.1% to 8.6 + 2% (basal vs 1st year; p < 0.001) and to 8.7 + 1.7% (1st year vs 2nd year; ns). The clinical inertia prevalence was 78.5% (at the moment of insulin therapy introduction), 56.2% (after 1 year; p = 0.001) and 62.2% (after 2 years; ns). Conclusion: Clinical inertia prevalence ranged from 56.2% to 78.5% at different moments of the insulin therapy (first 2 years and long term) of T2DM patients followed at a tertiary public Diabetes Center from an upper-middle income country with limited pharmacologic armamentarium.
 
Em uma população de pacientes com Diabetes Mellitus tipo 2 sob terapia com insulina, acompanhados no Centro de Diabetes da UNIFESP, um centro universitário, público e terciário, com arsenal farmacológico limitado, a porcentagem de pacientes que atingiram os alvos glicêmicos (individualmente ajustados, de acordo com a idade e a presença de comorbidades) variou entre 21,5% e 43,8%. Houve diferença estatística nas doses diárias de insulina, com impacto em redução dos valores de A1c somente no primeiro ano após a introdução da insulina e nenhuma diferença estatística nas doses diárias de insulina em anos subsequentes, apesar de níveis elevados de A1c. Portanto, concluimos que a prevalência de inércia clínica variou de 56,2% a 78,5% em diferentes momentos da terapia com insulina (primeiros 2 anos após a introdução e a longo prazo).
 
Keywords
Type 2 Diabetes Mellitus
Diabetes Complications
Glycosylated Hemoglobin (HbA1c)
Insulin Therapy
Diabetes Mellitus Tipo 2
Complicações Do Diabetes
Hemoglobina Glicosilada (HbA1c)
Terapia Com Insulina
URI
https://repositorio.unifesp.br/handle/11600/59242
Collections
  • PPG - Medicina (Endocrinologia e Metabologia) [264]

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    Insulin analogues in the treatment of diabetes in pregnancy 

    Negrato, Carlos Antonio; Montenegro Junior, Renan Magalhães; Von Kostrisch, Lilia Maria; Guedes, Maria Fatima; Mattar, Rosiane [UNIFESP]; Gomes, Marilia de Brito (Sociedade Brasileira de Endocrinologia e Metabologia, 2012-10-01)
    Pregnancy affects both maternal and fetal metabolism, and even in non-diabetic women, it exerts a diabetogenic effect. Among pregnant women, 2% to 14% develop gestational diabetes. Pregnancy can also occur in women with ...

  • Thumbnail

    Impacto de intervenções educativas na redução das complicações diabéticas: revisão sistemática 

    Menezes, Marcela Machado; Lopes, Camila Takao [UNIFESP]; Nogueira, Lilia de Souza (Assoc Brasileira Enfermagem, 2016)
    Objective: To identify in the literature evidence of the effectiveness and efficacy of educational interventions in reducing metabolic and/or vascular complications in adults with diabetes mellitus. Method: A systematic ...

  • Thumbnail

    Menor incidência de hipoglicemia noturna com o uso de insulina lispro comparada à insulina humana regular no tratamento de pacientes com diabetes do tipo 1 

    Wajchenberg, Bernardo Leo; Chacra, Antonio Roberto [UNIFESP]; Forti, Adriana Costa e [UNIFESP]; Ferreira, Sandra Roberta Gouvea [UNIFESP]; Monteiro, Odete de Oliveira [UNIFESP]; Lopes, Carla F.; Lerário, Antonio Carlos; Sena, Rita de Cássia; Kayath, Marcia J. (Sociedade Brasileira de Endocrinologia e Metabologia, 2000-04-01)
    Insulin lispro is a human insulin analog of rapid onset of action and duration, which mimics the physiological insulin profile after a meal. We have evaluated the safety and efficacy of lispro insulin in comparison with ...


DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV